Skip to main content

Table 3 Proinflammatory protein mRNAs expression in brainstem and cerebellum of MOG35-55 immunized mice treated with Veh or PEALut

From: A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis

 

Brainstem

Cerebellum

PID

PID

7

14

21

7

14

21

TNF-α/GADPH

Veh

1.0 ± 0.1

1.0 ± 0.3

1.0 ± 0.2

1.0 ± 0.2

1.0 ± 0.1

1.0 ± 0.2

MOG/Veh

2.5 ± 0.3

106.4 ± 33.3°°°

21.6 ± 6.5

1.6 ± 0.1

71.7 ± 19.7°°°

32.2 ± 14.1

MOG/PEALut

2.4 ± 0.4

52.6 ± 21.9*

15.9 ± 4.5

2.0 ± 0.2

31.9 ± 11.4**

16.5 ± 4.6

IL1-β/GADPH

Veh

1.0 ± 0.1

1.0 ± 0.2

1.0 ± 0.2

1.0 ± 0.1

1.0 ± 0.5

1.0 ± 0.5

MOG/Veh

2.4 ± 0.6

330.2 ± 77.8°°°

31.5 ± 6.9

2.1 ± 0.3

123.0 ± 78.6°

21.8 ± 8.8

MOG/PEALut

4.7 ± 2.0

174.7 ± 65.8**

23.7 ± 6.5

4.0 ± 0.8

18.8 ± 12.2*

14.8 ± 6.8

INFγ/GADPH

Veh

1.0 ± 0.2

1.0 ± 0.5

1.0 ± 0.4

1.0 ± 0.2

1.0 ± 0.4

1.0 ± 0.2

MOG/Veh

1.0 ± 0.3

115.2 ± 0.5°°°

19.2 ± 4.7

1.7 ± 0.5

37.8 ± 15.7°°

27.8 ± 8.1

MOG/PEALut

1.4 ± 0.3

35.7 ± 17.2**

19.3 ± 7.7

1.0 ± 0.1

6.9 ± 1.8*

22.5 ± 10.4

NLRP3/GADPH

Veh

1.0 ± 0.1

1.0 ± 0.1

1.0 ± 0.2

1.0 ± 0.1

1.0 ± 0.1

1.0 ± 0.1

MOG/Veh

0.7 ± 0.0

11.2 ± 1.4°°°

3.3 ± 0.6

0.7 ± 0.1

7.2 ± 2.0°°°

4.4 ± 0.8°

MOG/PEALut

1.0 ± 0.2

6.9 ± 2.2**

2.2 ± 0.6

0.9 ± 0.1

2.9 ± 0.6**

2.9 ± 0.6

  1. Mice were treated with Veh, MOG/Veh, or MOG/PEALut for 7, 14, and 21 days. Veh or PEALut treatments started at 11 PID. TNF-α, IL-1β, INFγ, and NLRP3 mRNAs values are reported as mean ± SEM. Data are shown as relative expression of Veh-treated values normalized to 1. n = 6 mice for each group. °p < 0.05, °°p < 0.01, and °°°p < 0.001 compared with the Veh-treated group. *p < 0.05 and **p < 0.01 compared with the MOG/Veh